India Health Budget: Nominal Gains Mask Real-Term Decline

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorRiya Kapoor|Published at:
India Health Budget: Nominal Gains Mask Real-Term Decline
Overview

The Union Budget 2026-27 presents a nominal increase in health and AYUSH allocations, reaching approximately ₹1.06 lakh crore. However, this rise is substantially diminished when adjusted for high medical inflation, resulting in real-term funding levels that are less than actual spending in 2020-21. The sector's share of GDP and the total Union budget has also declined, signaling a reduced governmental priority for public health infrastructure and services despite the introduction of new initiatives like Biopharma Shakti.

1. THE SEAMLESS LINK

The increased nominal budget for health and AYUSH ministries, while appearing substantial on paper, fails to account for the rapid escalation of healthcare costs. This fiscal maneuver risks eroding India's capacity to deliver essential health services, a critical concern given the nation's demographic shifts and ongoing public health challenges.

The Inflationary Squeeze on Healthcare Allocations

The Union Budget for 2026-27 allocated approximately ₹1.06 lakh crore to the Ministry of Health and Family Welfare. This figure represents a nominal increase, but when adjusted for healthcare inflation, which is running at 11.5% to 15% annually, the real-term growth is significantly muted, potentially showing a decline compared to previous years. Reports indicate that for 2025-26 Budget Estimates, the real-term allocation was already 4.7% to 7% less than the actual expenditure in 2020-21. This suggests a contraction in the actual services that can be provided, despite higher headline figures. Furthermore, the health sector's proportion of the national GDP has decreased from 0.37% in 2020-21 to an estimated 0.29% in 2025-26. This trend is mirrored in the sector's share of the total Union Budget, which has fallen from 2.26% to approximately 2.05% over the same period, indicating a strategic de-prioritization.

Shifting Priorities: Public Health Programs Face Funding Strain

Analysis of specific program allocations reveals a divergence in government focus. While schemes promoting commercial interests appear to be favored, vital public health programs face budgetary constraints. The National Health Mission (NHM), a cornerstone for primary and secondary healthcare, maternal and child health, and disease control, has seen its central share for state transfers diminish significantly over the past decade, falling from 75.9% in 2014-15 to 43% in 2024-25. Although the overall NHM allocation for 2026-27 is noted to have increased to ₹39,390 crore, concerns persist regarding the central government's declining direct contribution to states and the potential impact on essential services and frontline health workers like ASHAs. In contrast, the Pradhan Mantri Jan Arogya Yojana (PMJAY), a public-private insurance scheme, continues to receive substantial funding. While specific figures for the prompt's 2024-25 BE allocation are not directly verifiable in search results, reports indicate PMJAY is allocated around ₹9,500 crore for 2026-27, representing a modest increase over the previous year, despite ongoing criticisms regarding its effectiveness for the most marginalized populations and its tendency to benefit the private sector.

Biopharma Push and Commercial Healthcare Initiatives

Significant emphasis has been placed on boosting India's pharmaceutical and healthcare industries. The introduction of the 'Biopharma Shakti' initiative, with an outlay of ₹10,000 crore over five years, aims to establish India as a global hub for biologics and biosimilars, fostering domestic research and manufacturing. This program includes setting up new National Institutes of Pharmaceutical Education and Research (NIPERs) and upgrading existing ones. Additionally, proposals to develop medical tourism hubs and strengthen the digital health ecosystem suggest a strategic push towards commercializing healthcare services, potentially utilizing public resources to serve private sector interests and attract international patients. Measures like customs duty exemptions on specific cancer and rare disease drugs aim to reduce patient out-of-pocket expenditure, though the broader impact on public health system capacity remains a concern.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.